CF
IMNM icon

Corebridge Financial’s Immunome IMNM Stock Holding History

Corebridge Financial’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,735
Closed -$234K – 1320
2025
Q1 		$234K Buy
34,735
+9,179
+36% +$88.1K ﹤0.01% 1981
2024
Q4 		$271K Sell
25,556
-1,929
-7% -$23.3K ﹤0.01% 1994
2024
Q3 		$402K Sell
27,485
-170
-0.6% -$2.42K ﹤0.01% 1842
2024
Q2 		$335K Buy
+27,655
New +$433K ﹤0.01% 1904

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Corebridge Financial's IMNM Position: Q2 2025 in Review

Corebridge Financial sold out of Immunome (IMNM) in Q2 2025, closing a stake of 34,735 shares — an estimated $234K sold.

Corebridge Financial first reported a position in IMNM in Q2 2024 and held it in 4 quarters. The position peaked at $402K in Q3 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q2 2025.

  • Corebridge Financial reported no remaining Immunome position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 34,735 Immunome shares in Q2 2025, an estimated $234K.
  • Corebridge Financial first reported a position in Immunome in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Immunome position peaked at $402K in Q3 2024.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.